THU0187 IMPACTS OF BODY MASS INDEX ON CLINICAL RESPONSE OF NOVEL SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: 1-YEAR RESULTS FROM A PART 2 OF PHASE I/III RANDOMIZED CONTROLLED TRIAL
Authors: D. Yoo, R. Westhovens, P. Wiland, M. Zawadzki, D. Ivanova, A. Berrocal, E. Chalouhi, É. Balázs, S. Shevchuk, S. J. Lee, S. H. Kim, N. Han, Y. Jung
Journal: Annals of the Rheumatic Diseases (2020)

Background: In the post-hoc analysis of PLANETRA, a Phase III randomized controlled trial (RCT), no significant association was found between body mass index (BMI) and clinical responses in rheumatoid arthritis (RA) patients using weight-based intravenous (IV) infliximab (3 mg/kg every 8 weeks) 1,2 . Since the subcutaneous (SC) formulation of CT-P13 which was approved from EMA after demonstrating non-inferiority compared to CT-P13 IV is a fixed-dose of 120 mg biweekly, it is meaningful to evaluate the impact of BMI on clinical response of CT-P13 SC 3,4 . Objectives: This report is to investigate post-hoc impact of BMI on clinical responses of CT-P13 SC 120 mg in Part 2 of a Phase I/III RCT in active RA patients throughout the 1-year treatment period. Methods: A total of 165 patients who received at least one full dose of CT-P13 SC (after IV induction at Weeks 0 and 2) in the initial treatment stage before Week 30 and who had at least one efficacy evaluation result after Week 6 or thereafter were included in this analysis. Patients were categorized into 3 groups; under/normal weight (&lt;25kg/m 2 ), overweight (≥25kg/m 2 , &lt;30kg/m 2 ), and obesity (≥30kg/m 2 ) based on the WHO BMI classification. Baseline characteristics, mean change from baseline in disease activity by DAS28 (CRP), remission (DAS28 [CRP]≤2.6) and low disease activity (LDA; 2.6&lt;DAS28 [CRP]≤3.2), duration (week) of LDA, EULAR response, and ACR response were evaluated among the 3 BMI groups. Results: In the under/normal weight (n=63), overweight (n=61), and obesity (n=41) groups, the mean±SD of age (years) (48.7±14.00, 51.5±10.93, 53.8±10.62) and the mean±SD of RA duration (years) (6.4±6.00, 8.2±9.27, 5.4±4.72) were comparable. At baseline, the rates of high disease activity (90.5%, 90.2%, 87.8%; DAS28 [CRP]&gt;5.1) were similar among the groups. All other baseline and disease characteristics including gender, race, and other disease activity parameters were also comparable among the groups. The rate of remission or LDA (Figure 1), the mean change from baseline of DAS28 (CRP) (-3.3, -3.1, -3.3 at Week 54), duration of LDA up to Week 54 (26.2, 29.2, 27.9 weeks), and the good or moderate EULAR responder rates (84.1%, 80.3%, 90.2% at Week 54) were all comparable among the groups and there were no statistically significant differences (p-value&gt;0.05). The ACR responder rates were also comparable among the groups except for the ACR70 at Weeks 2 and 6 which were obtained following 2 IV infusions in the IV dose loading phase. Absolute value of Pearson correlation coefficient was below 0.06 between BMI at screening and mean change from baseline in DAS28 (CRP) during CT-P13 SC treatment from Weeks 14 to 54, indicating that correlation between two measurements was weak and was not statistically significant (p-value&gt;0.05) (Figure 2). Figure 1. Remission or LDA Based on DAS28 (CRP) Figure 2. DAS28 (CRP) improvement Conclusion: These post-hoc results showed that there was no impact of BMI on the clinical responses of CT-P13 SC 120 mg biweekly in RA patients. Therefore, CT-P13 SC 120 mg could be a reasonable therapeutic option regardless of BMI. References: [1]Yoo D.H., et al. Ann Rheum Dis, 2013;72:1613-20. [2]Yoo D.H., et al. Ann Rheum Dis, 2016;75:1005. [3]Westhovens R., et al. Ann Rheum Dis, 2019;78:A1158 [4]Westhovens R., et al. Arthritis Rheumatol. 2019;71 (suppl 10). Disclosure of Interests: DaeHyun Yoo Grant/research support from: Celltrion, Inc, Consultant of: Celltrion, Inc, Speakers bureau: Celltrion Healthcare, Inc, Rene Westhovens Grant/research support from: Celltrion Inc, Galapagos, Gilead, Consultant of: Celltrion Inc, Galapagos, Gilead, Speakers bureau: Celltrion Inc, Galapagos, Gilead, Piotr Wiland Grant/research support from: Celltrion, Inc, Speakers bureau: Novartis, Pfizer, Abbvie, Gedeon-Richter, Lilly, Roche, Sandoz, Marek Zawadzki Grant/research support from: Celltrion, Inc, Delina Ivanova Grant/research support from: Celltrion, Inc, Alfredo Berrocal Grant/research support from: Celltrion, Inc, Speakers bureau: Pfizer, Elias Chalouhi Grant/research support from: Celltrion, Inc, Éva Balázs Grant/research support from: Celltrion, Inc, Consultant of: Amgen, Sergii Shevchuk Grant/research support from: Celltrion, Inc, Sang Joon Lee Shareholder of: Celltrion, Inc, Employee of: Celltrion, Inc, Sung Hyun Kim Shareholder of: Celltrion, Inc, Employee of: Celltrion, Inc, NooRi Han Employee of: Celltrion, Inc., YooBin Jung Employee of: Celltrion, Inc